On the road to developing new therapeutic drugs for osteoporosis and other bone degenerative diseases.
Osteoporosis is a disease that causes bones to fracture easily due to a reduction in both bone mass and quality. Aging is one of its leading causes, and it is estimated that around 200 million people are affected worldwide. Fractures of the femoral neck–the connection between the femur and the hip joint–or of vertebrae can leave a person bedridden which increases the need for care, reduces quality of life and systemic function, and increases mortality.
Bone is a living tissue that is repeatedly broken down (bone resorption) and remade (bone formation) little by little every day. If this balance collapses and bone resorption exceeds bone formation, bone density decreases and can lead to osteoporosis. Several medications are available to treat this disease, but the number of drugs that promote bone formation are far fewer compared to those that suppress bone resorption. The development of therapeutic agents that regenerate bones is highly desired.
Sirtuins are enzymes that play important roles in controlling aging, stress responses, various areas of the metabolism, and several other body functions. In mammals, there are seven types of sirtuins, SIRT1 to SIRT7. Although SIRT7 has been reported to be involved in cancer and lipid metabolism, its role in bone tissue and bone aging was unknown.
1. The effect of SIRT7 on bone formation
Recent experiments performed by a research group led by scientists from Kumamoto University, Japan showed that mice lacking the SIRT7 gene had reduced bone mass. A bone morphometry analysis showed that bone formation and the number of osteoblasts (bone-building cells) had been reduced. Furthermore, the researchers obtained similar results using osteoblast-specific SIRT7 deficient mice, thereby showing that (osteoblast-specific) SIRT7 is important for bone formation.
2. Expression of sirtuins in bone tissue of old mice
Reduced bone formation is common in people with osteoporosis, and the mechanism for this reduction is not well known. To clarify the mechanism, the researchers compared sirtuin (SIRT1, 6, and 7) expression in the skeletal tissue of young and old mice, and found that SIRT7 decreased with age. They then considered that this decrease in SIRT7 in the older specimens may be associated with decreased osteogenesis, and may even be a cause of osteoporosis.
3. The effect of SIRT7 on osteoblast differentiation
When the researchers cultured osteoblasts (in vitro) with decreased SIRT7 expression in their next experiment, the formation of a bone-like mass (calcified nodule) was markedly suppressed compared to cultures of normal osteoblasts. Additionally, the expression of genes indicating osteoblast differentiation was also decreased, thereby revealing that SIRT7 controls the differentiation of osteoblasts.
4. Transcriptional activation of SP7/Osterix by SIRT7
To clarify the mechanism by which osteoblastic SIRT7 positively regulates the differentiation of osteoblasts, researchers investigated the transcription activity of the gene expression regulatory factor essential for osteoblast differentiation. They found that the transcription activity of SP7 (also known as Osterix), a protein known to induce differentiation of pre-osteoblasts into mature osteoblasts and osteocytes, was markedly decreased in osteoblasts that lacked the SIRT7 gene.
They also realized that to get high transcription activation of SP7/Osterix, it is important for SIRT7 to deacylate the 368th lysine residue of the SP7/Osterix protein. In other words, SIRT7 enhances the transcriptional activity of SP7/Osterix by chemically modifying it (deacylating the 368th lysine residue). Furthermore, the researchers were able to recover osteoblast functionality in the calcified nodule formation by introducing a mutant SP7/Osterix, which deacylated the 368th lysine of SP7/Osterix, into the osteoblasts that had reduced SIRT7 expression.
The research group is confident that their results show a new mechanism for SIRT7 as a deacylating enzyme important for transcriptional activation of the gene expression regulator SP7/Osterix and is essential for osteoblast differentiation.
“In situations where SIRT7 does not work sufficiently, such as in an older individual, osteoblast formation is impaired due to low SP7/Osterix transcriptional activity. We believe that this decreased osteogenesis is associated with osteoporosis,” said study leader Dr. Tatsuya Yoshizawa of Kumamoto University. “Our results, show that the regulatory pathway of SIRT7 – SP7 / Osterix is a promising target for new therapeutic agents to treat decreased osteogenesis and osteoporosis.”
The Latest on: Bone degenerative diseases
via Google News
The Latest on: Bone degenerative diseases
- All About Animals: Getting a Grip on Arthritis on February 18, 2019 at 2:40 pm
One is arthritis, also called osteoarthritis or degenerative joint disease. It occurs when cartilage is worn away, thus exposing bone and nerves. Normally, arthritis develops due to being ... […]
- The Next Great Small Cap Med-Tech Story? on February 18, 2019 at 8:48 am
SI-BONE (NASDAQ: SIBN) is a $441M medical device company ... such as knee and hip arthritis and degenerative disc disease, each of which has surgical solutions where an implant is used and a multi-bil... […]
- Senior Living: Here’s the deal on degenerative joint diseases on February 15, 2019 at 9:00 am
degenerative arthritis, deposition arthritis and inflammatory arthritis. Within each category are numerous sub types. There is a lot to say. I will have to break this up into several columns. Osteoart... […]
- Gaharwar, team develop new therapeutic approach to treating osteoarthritis on February 14, 2019 at 12:51 pm
a degenerative disease that affects nearly 27 million Americans and is caused by breakdown of cartilage that can lead to damage of the underlying bone. As America’s population ages, the number of oste... […]
- Glenohumeral Degenerative Disease: Osteoarthritis on February 14, 2019 at 7:34 am
If necessary a bone graft wedge can be obtained from the previously ... “Retrospective analysis of arthroscopic management of glenohumeral degenerative disease”. Arthroscopy. vol. 26. 2010. pp. 1451-5 ... […]
- Osteoarthritis Market 2017-2025 : Eli Lilly and Company, Johnson & Johnson Limited, Abbott Laboratories, and Novartis AG on February 14, 2019 at 5:38 am
is a degenerative disease of the joint involving the joint lining, cartilage, underlying bone, and ligaments. The diseases generally affects the knee, hand, hip, and spine and is characterized by stif... […]
- PrinterPrezz to Work With SI-BONE to Speed Innovation in Metal 3D Printed Orthopedic Medical Devices on February 12, 2019 at 4:01 am
and we continue to push forward our R&D to deliver solutions for those who can benefit from surgical treatment of SI joint disorders,” said Scott Yerby, Chief Technology Officer of SI-BONE. “Working w... […]
- Patient finds freedom in treatment on February 11, 2019 at 9:19 pm
She’s inspiring, fun loving and full of energy, but throughout the years, her chronic pain from psoriatic arthritis, former surgeries, degenerative disc disease, bone spurs and rotator cuff ... […]
- Kuros Biosciences Signs Agreement to Supply SeaSpine with Bone Graft Incorporating Kuros’s Advanced Submicron Surface Technology on February 10, 2019 at 10:00 pm
SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders. Under the agreement Kuros will supply the bone graft in various forms and SeaSpine ... […]
via Bing News